Reduced Chemotherapy Duration: A Good Idea?
Over the past three decades, survival outcomes of high-risk stage II and stage III colon cancer have improved with the use of adjuvant chemotherapy. Oxaliplatin and fluoropyrimidine combination regimens, given for 6 months, are the current standard of care. However, chronic peripheral neuropathy can result as a side effect of oxaliplatin use. Investigators have questioned whether the recommended duration of adjuvant therapy is necessary. This review discusses the history of adjuvant therapy for colon cancer and provides a rationale for an ongoing clinical trial collaboration addressing the optimal duration of adjuvant therapy.
KeywordsColon cancer Adjuvant therapy 5-fluorouracil Oxaliplatin Chemotherapy-induced sensory neuropathy Peripheral neuropathy
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
- 2.O'Connell MJ. Current status of adjuvant therapy for colorectal cancer. Oncology (Williston Park). 2004;18:751–5. discussion 755–8.Google Scholar
- 9.Haller D, Tabernero J, Maroun J, et al.: First efficacy findings from a randomized phase III trial of capecitabine + oxaliplatin vs. bolus 5-FU/LV for stage III colon cancer (NO16968/XELOXA study) Presented at the Joint ECCO 15 - 34TH ESMO Multidisciplinary Congress, Berlin September 20–24, 2009.Google Scholar
- 10.•• Kuebler JP, Wieand HS, O'Connell MJ, et al.: Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007, 25:2198–2204. This study provides the rationale for the use of lower cumulative doses of oxaliplatin in the adjuvant setting.PubMedCrossRefGoogle Scholar
- 11.•• Andre T, Boni C, Navarro M, et al.: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009, 27:3109–3116. A report of the updated results from the MOSAIC trial demonstrating an overall survival benefit with oxaliplatin in the adjuvant setting. PubMedCrossRefGoogle Scholar
- 18.Link KH, Kornmann M, Staib L, et al. Increase of survival benefit in advanced resectable colon cancer by extent of adjuvant treatment: results of a randomized trial comparing modulation of 5-FU + levamisole with folinic acid or with interferon-alpha. Ann Surg. 2005;242:178–87.PubMedCrossRefGoogle Scholar
- 20.Alberts SR, Sargent DJ, Smyrk TC, et al.: Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III Trial N0147. [Abstract CRA3507]. Presented at the 2010 ASCO Annual Meeting Chicago, IL; June 4–8, 2010.Google Scholar
- 21.Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery. Available at http://www.clinicaltrials.gov/ct2/show/NCT01150045. Assessed February 13, 2011.
- 22.FOLFOX-4 3 months Versus 6 Months and Bevacizumab as Adjuvant Therapy for Patients With Stage II/III Colon Cancer (TOSCA). Available at http://www.clinicaltrials.gov/ct2/show/NCT00646607. Assessed February 13, 2011.
- 23.Combination Chemotherapy After Surgery in Treating Patients With High-Risk Stage II or Stage III Colorectal Cancer. Available at http://www.clinicaltrials.gov/ct2/show/NCT00749450. Assessed February 13, 2011.
- 24.Combination Chemotherapy for 3 Months or 6 Months in Treating Patients With Stage III Colon Cancer. Available at http://www.clinicaltrials.gov/ct2/show/NCT00958737. Assessed February 13, 2011.
- 25.A Multicenter Trial Investigating the Duration of Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX Regimen for Patients With High Risk Stage II or Stage III Colon Cancer. Available at http://www.clinicaltrials.gov/ct2/show/NCT01308086?term=NCT01308086. Assessed June 6, 2011.